Scribe Therapeutics, Inc.
SCTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001853921
No open-market purchases or sales by Scribe Therapeutics, Inc. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q3 2026, worth $297.1M in total; ARK Invest is the only superinvestor holding it.
Key figures
- Market capClose on Nov 20, 2026
- $228.6M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +62 vs. previous quarter
- 62
- 13F valueReported value at the end of Q3 2026
- $297.1M
- Superinvestors holdingAt the end of Q3 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, Q3 FY2026
- $1.64M
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.67M
- Shares sold short
- Change
- +553.3K
- +49.5% vs. previous
- Days to cover
- 4.01
- At average daily volume
Superinvestors holding SCTX, Q3 2026
Go to the superinvestors tab1 superinvestor reports holding Scribe Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Scribe Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2026 (view filing)7:09 PM ET | Jul 27 | 2 days | Andreessen Marc L and 5 others10% Owner | PPurchase | +333.3K | $15.00 | +$5.00M | +16.2%2.39M after | |
| Jul 29, 2026 (view filing)6:50 PM ET | Jul 27 | 2 days | Gordon Carl LDirector | PPurchase | +1.00M | $15.00 | +$15.0M | +286.7%1.35M after | Duplicate filing |
| Jul 29, 2026 (view filing)6:47 PM ET | Jul 27 | 2 days | OrbiMed Advisors LLC and 1 otherDirector | PPurchase | +1.00M | $15.00 | +$15.0M | +286.7%1.35M after | |
| Jul 28, 2026 (view filing)9:30 PM ET | Jul 24-28 | 4 days | Avoro Capital Advisors LLC and 2 othersDirector, 10% Owner, Other: See Remarks | PPurchaseCommon Stock, par value $0.0001 per share | +2.39M | $15.16 | +$36.3M | +342.8%3.09M after | 3 lots |
| Jul 27, 2026 (view filing)9:42 PM ET | Jul 23 | 4 days | Lucas SvetlanaChief Business Officer | PPurchase | +3.00K | $15.00 | +$45.0K | New position3.00K after | |
| Jul 27, 2026 (view filing)9:20 PM ET | Jul 23 | 4 days | Parrot DavidChief Financial Officer | PPurchase | +2.67K | $15.00 | +$40.0K | New position1.33K after | 2 lots |
Top 10 13F holders, Q3 2026
See all 62 holdersThe largest institutional positions in Scribe Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AH Capital Management, L.L.C. | 3,082,725 | $56.7M | 0.29% | +3,082,725 | New |
| Avoro Capital Advisors LLC | 2,598,973 | $47.8M | 0.49% | +2,598,973 | New |
| Ra Capital Management, L.P. | 1,802,178 | $33.2M | 0.33% | +1,802,178 | New |
| OrbiMed Advisors LLC | 1,348,825 | $24.8M | 0.46% | +1,348,825 | New |
| Perceptive Advisors LLC | 920,341 | $16.9M | 0.32% | +920,341 | New |
| ARK Investment Management LLCSuperinvestorARK Invest | 786,921 | $14.5M | 0.08% | +786,921 | New |
| Baker Bros. Advisors LP | 688,691 | $12.7M | 0.06% | +688,691 | New |
| Price T Rowe Associates Inc | 684,706 | $12.6M | 0.00% | +684,706 | New |
| BlackRock, Inc. | 679,786 | $12.5M | 0.00% | +679,786 | New |
| Sanofi | 500,000 | $9.20M | 1.46% | +500,000 | New |
Holders of 5% or more of SCTX
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Scribe Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 13D | 16.37%3.09M shares | New | Jul 30, 20261 filing | Jul 30, 2026 | SEC |
| AH Bio Fund II, L.P. | 13G | 16.30%3.08M shares | New | Nov 16, 20261 filing | Nov 16, 2026 | SEC |
| Ra Capital Management, L.P. | 13G | 9.60%1.80M shares | New | Aug 3, 20261 filing | Aug 3, 2026 | SEC |
| Eli Lilly & Co | 13D | 7.30%1.39M shares | New | Jul 30, 20261 filing | Jul 30, 2026 | SEC |
| OrbiMed Advisors LLC | 13D | 7.20%1.35M shares | New | Jul 29, 20261 filing | Jul 29, 2026 | SEC |